Session » Systemic Lupus Erythematosus - Clinical Aspects and Treatment Poster Session II
-
Abstract Number: 1781
Comparative Efficacy and Safety of Tacrolimus, Mycophenolate Mofetil, and Cyclophosphamide As Induction Therapy for Lupus Nephritis: A Bayesian Network Meta-Analysis of Randomized Controlled Trials
-
Abstract Number: 1782
a Double-Blind, Randomized, Parallel-Group Study of Hydroxychloroquine on Cutaneous Lupus Erythematosus in Japan
-
Abstract Number: 1783
Dietary Fish Oil Supplementation Raises Serum Essential Fatty Acid Concentrations in Patients with Systemic Lupus Erythematosus and Correlates with Improvements in Inflammation and Pain
-
Abstract Number: 1784
Treatment with Belimumab in SLE Does Not Impair Antibody Response to 13-Valent Pneumococcal Conjugate Vaccine
-
Abstract Number: 1785
Clinical Characteristics and Relative Factors of Infections in Southern Chinese Patients with Systemic Lupus Erythematosus
-
Abstract Number: 1786
Improvements in Health-Related Quality of Life and Fatigue Following Administration of an IL-6 Monoclonal Antibody (PF-04236921) in an Enriched Population of Subjects with Active SLE
-
Abstract Number: 1787
Innate Immunity, Arterial Inflammation and Vascular Stiffness in Patients with Systemic Lupus Erythematosus
-
Abstract Number: 1788
Lipoprotein Subfractions and Cardiovascular Disease in Systemic Lupus Erythematosus
-
Abstract Number: 1789
Infections Observed in Rituximab Treated Patients with Refractory Systemic Lupus Erythematosus (SLE): Results from a National Multicentre Register
-
Abstract Number: 1790
Mycophenolate Mofetil Suppresses Humoral Response to Pneumococcal Vaccine in Patients with Systemic Lupus Erythematosus and Other Autoimmune Diseases
-
Abstract Number: 1791
Does Renin-Angiotensin System Blockade Protect Lupus Nephritis Patients from Atherosclerotic Cardiovascular Events? a Case-Control Study
-
Abstract Number: 1792
Optimal Monitoring for Coronary Heart Disease Risk in Systemic Lupus Erythematosus Patients: a Systematic Review
-
Abstract Number: 1793
Is There a Relationship Between Antimalarial Treatment and Elevated Muscle Enzymes in Systemic Lupus Erythematosus
-
Abstract Number: 1794
Unexplained Decline in Rates of Cardiovascular Events in a Large Cohort of SLE Patients
-
Abstract Number: 1795
Long-Term Safety and Efficacy of Tacrolimus for Lupus Nephritis Patients in Real World Setting -Results from 5 Year Interim Analysis of Post Marketing Surveillance of 1376 Patients in Japan-
-
Abstract Number: 1796
Progression of Atherosclerosis Might be Prevented By Decrease of Serum Resistin Level after Glucocorticoid Therapy in Patients with Systemic Autoimmune Disease
-
Abstract Number: 1797
Insulin Resistance Is Not Associated with Increased Risk of Subclinical Atheromatosis in Patients with Systemic Lupus Erythematosus from Northern Spain
-
Abstract Number: 1798
Progression of Noncalcified and Calcified Coronary Plaque (by CT Angiography) in SLE
-
Abstract Number: 1800
A Novel Anti-CD28 Domain Antibody Antagonist Shows a Favorable Pharmacokinetic, Pharmacodynamic and Safety Profile
-
Abstract Number: 1801
Hydroxychloroquine Retinopathy: Application of the 2011 Screening Guidelines in an Academic Practice
-
Abstract Number: 1802
Hydroxychloroquine Level Variants and Predictors in a Connective Tissue Disease Population
-
Abstract Number: 1803
Serum Adipocyte Fatty Acid-Binding Protein Level Is Elevated in Patients with Systemic Lupus Erythematosus (SLE) but Not Associated with Biophysical Markers of Cardiovascular Disease
-
Abstract Number: 1804
Association of the Metabolic Syndrome (MetS) with Vascular Complications, End Stage Renal Failure (ESRF) and Mortality in Patients with Systemic Lupus Erythematosus (SLE): A Cohort Analysis
-
Abstract Number: 1805
Functional and Mechanistic Characterization of Anifrolumab, a Fully Human, Anti-IFNAR1 Monoclonal Antibody for the Treatment of Systemic Lupus Erythematosus
-
Abstract Number: 1806
Hydroxychloroquine Serum Levels and Flares of Systemic Lupus Erythematosus: A Longitudinal Cohort Analysis
-
Abstract Number: 1807
Estimated Sodium and Potassium Intake Are Associated with Blood Pressure in Patients with Systemic Lupus Erythematosus
-
Abstract Number: 1808
Exercise Is Associated with Improved Cardiometabolic Risk Factors in Patients with SLE
-
Abstract Number: 1809
Real Life Implementation of Lupus Nephritis Randomized Controlled Trials
-
Abstract Number: 1810
A Five-Year Follow-up of Microvascular Dysfunction and Coronary Artery Disease in SLE: Results from a Community-Based Lupus Cohort
-
Abstract Number: 1811
Depression and Progression of Subclinical Cardiovascular Disease in Systemic Lupus Erythematosus
-
Abstract Number: 1812
The First Randomized Control Trial to Evaluate the Effectiveness of Bortezomib for Refractory Systemic Lupus Erythematosus
-
Abstract Number: 1813
Novel Mechanism of Action of Anti-Malarial Drugs in the Inhibition of Type I Interferon Production
-
Abstract Number: 1814
Efficacy of Isoniazid Chemoprophylaxis in Lupus Nephritis Patients
-
Abstract Number: 1815
Hydroxychloroquine Blood Levels in Systemic Lupus Erythematosus: Clarifying Dosing Controversies and Improving Adherence
-
Abstract Number: 1816
Long-Term Outcome of Tacrolimus Therapy As a Maintenance Strategy in Patients with Lupus Nephritis
-
Abstract Number: 1817
Myocardial Tissue Characterization with Native Myocardial T1 Mapping in SLE Patients with Chest Pain
-
Abstract Number: 1818
Cyclophosphamide and Cumulative Steroid Dose Associated with Higher Risk of Infections in Patients with Lupus Nephritis
-
Abstract Number: 1819
Comparison of Electrocardiographic ST-T Changes and QTc Duration in Patients with Systemic Lupus Erythematosus and Rheumatoid Arthritis
-
Abstract Number: 1820
Prevalence and Risk-Factors for Asymptomatic Coronary-Artery Calcifications in Young Patients with Systemic Lupus Erythematosus
-
Abstract Number: 1821
Leptin, Adiponectin, and Resistin As Serum Markers of Fatigue in Systemic Lupus Erythematosus: A Pilot Study
-
Abstract Number: 1822
Pharmacokinetics of the Selective B-Cell Lymphoma-2 (Bcl-2) Inhibitor, ABT-199, in Female Subjects with Systemic Lupus Erythromatosus
-
Abstract Number: 1823
Visceral Adiposity in Premenopausal Lupus Patients: Correlation with Systemic Inflammation
-
Abstract Number: 1824
Tripterygium Wilfordii for the Treatment of Systemic Lupus Systematosus: Meta-Analysis of Randomized Controlled Trials
-
Abstract Number: 1825
Osteoprotegerin Is Associated with Lupus and with Coronary Artery Calcification
-
Abstract Number: 1826
Small LDL-P Increases with Increased Disease Activity in SLE
-
Abstract Number: 1827
Plasma Myeloperoxidase Levels Are Inversely Associated with Carotid Plaque in SLE
-
Abstract Number: 1828
Target Modulation of a Type I Interferon Gene Signature and Pharmacokinetics of Anifrolumab in a Phase IIb Study of Patients with Moderate to Severe Systemic Lupus Erythematosus
-
Abstract Number: 1829
Heart Rate Variability Is Associated with SLE Flare and with TNF- and IFN-Mediated Signaling
-
Abstract Number: 1830
Periodontal Disease in Lupus Erythematosus and Cardiovascular Risk Factors
-
Abstract Number: 1831
Initial Risk Factor Profile and Long-Term Cardiovascular Outcome in Women with Systemic Lupus Erythematosus
-
Abstract Number: 1832
Recurrence-Rate of Thrombotic Events in SLE Patients Negative for Antiphospholipid Antibodies
-
Abstract Number: 1833
Musculoskeletal Complications of Systemic Lupus Erythematosus: Risk Factors for and Prevalence of Avascular Necrosis and Osteoporosis
-
Abstract Number: 1834
Total Hip Arthroplasty Outcomes: A 17 Year Experience in a Single-Center: Is Systemic Lupus Erythematosus a Real Risk Factor for Adverse Outcomes?
-
Abstract Number: 1835
Systemic Lupus Erythematosus Does Not Increase Risk of Adverse Events in the First 6 Months after Total Knee Replacement
-
Abstract Number: 1836
Standardized Incidence Ratio (SIR), Time Trend and Risk Factors of Avascular Bone Necrosis (AVN) in Patients with Systemic Lupus Erythematosus (SLE)
-
Abstract Number: 1837
Predictability of Musculoskeletal Flares and Hand Deformities in Systemic Lupus Erythematosus By High Resolution Ultrasound : 5-Year Clinical and Imaging Prospective Follow-up Study
-
Abstract Number: 1838
Joint Ultrasonography May be Useful to Assess Disease Activity in Systemic Lupus Erythematosus (SLE) Patients: A Prospective Multicenter Study
-
Abstract Number: 1839
Safety and Immunogenicity of Quadrivalent Human Papilloma Virus (qHPV) Vaccine (Gardasil®) in Systemic Lupus Erythematous (SLE), Phase I Trial Completion
-
Abstract Number: 1840
How Good a Job Are We Rheumatologists Doing in Screening for Hepatitis B and C before Immuno-Suppressive/s Initiation in SLE?
-
Abstract Number: 1841
Meningitis in Systemic Lupus Erythematosus Patients: Epidemiologic Profile of Listeria Monocytogenes Infection. a Single-Center Study
-
Abstract Number: 1842
Systemic Lupus Erythematosus and Chikungunya Fever: Interactions during the 2014 Outbreak in Martinique
-
Abstract Number: 1843
Bloodstream Infections in Systemic Lupus Erythematosus Patients Are Associated with Severe Lupus Flares
-
Abstract Number: 1844
Risk Factors for Complicated Pneumonia in Systemic Lupus Erythematosus (SLE)